Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor

NCT04145349 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04145349
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04145349 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
Lead sponsor
Eli Lilly and Company
Phase
Phase 1/2
Overall status
Completed
Start date
January 22, 2020
Completion date
January 23, 2026
Enrollment
30 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

desmoplastic small round cell tumor